The current study tested the hypothesis that endogenous 20-hydroxyeicosatetraenoic acid (20-HETE) contributes to the increase in intracellular calcium ([Ca 2ϩ respectively. These results demonstrate that 20-HETE plays a significant role in the renal microvascular smooth muscle cell [Ca 2ϩ ] i response to P2X receptor activation.
ATP. ATP (100 M) increased vascular smooth muscle cell [Ca 2ϩ ] i by 372 Ϯ 93 and 163 Ϯ 55 nM in the presence of DDMS or 20-HEDE, respectively. The P2X receptor agonist, ␣,␤-methylene-ATP (10 M), increased myocyte [Ca 2ϩ ] i by 78 Ϯ 12 nM, and this response was significantly attenuated by DDMS (40 Ϯ 15 nM). In contrast, the vascular smooth muscle cell [Ca 2ϩ ] i evoked by the P2Y agonist, UTP (100 M), was not altered by DDMS or 20-HEDE. The effect of 20-HETE on [Ca 2ϩ ] i was also assessed, and the peak increases in [Ca 2ϩ ] i averaged 62 Ϯ 12 and 146 Ϯ 70 nM at 20-HETE concentrations of 1 and 10 M, respectively. These results demonstrate that 20-HETE plays a significant role in the renal microvascular smooth muscle cell [Ca 2ϩ ] i response to P2X receptor activation.
ATP induces vasoconstriction by activating P2 receptors on preglomerular microvascular smooth muscle cells (Inscho et al., 1995 (Inscho et al., , 1998 Eltze and Ullrich, 1996) . This vasoconstriction seems to depend on activation of P2X and P2Y receptors. ATP-mediated afferent arteriolar vasoconstriction is largely dependent on the influx of extracellular Ca 2ϩ , and the sustained vasoconstriction is maintained by Ca 2ϩ influx through voltage-dependent L-type Ca 2ϩ channels (Inscho et al., 1995 (Inscho et al., , 1999b Navar et al., 1996; Inscho and Cook, 2002) . Activation of P2X and P2Y receptors on microvascular smooth muscle cells stimulates an increase in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) by distinct Ca 2ϩ signaling pathways (Inscho et al., 1999a,b) . P2X receptors are described as having two membrane-spanning domains and function as ligand-gated channels that allow influx of extracellular cations including Ca 2ϩ (el-Moatassim et al., 1992; Dubyak and el-Moatassim, 1993; Abbracchio and Burnstock, 1994; Fredholm et al., 1994; Evans et al., 1998: Ralevic and White et al., 2001) . Interestingly, inactivation of P2X receptors on preglomerular microvessels inhibits autoregulatory behavior (Mitchell and Navar, 1993; Inscho et al., 1996 Inscho et al., , 2003 Majid et al., 1999) . In contrast, P2Y receptors have seven membranespanning domains coupled to G proteins and increase [Ca 2ϩ ] i , in part, by stimulating mobilization of Ca 2ϩ from intracellular stores (el-Moatassim et al., 1992; Dubyak and el-Moatassim, 1993; Abbracchio and Burnstock, 1994; Fredholm et al., 1994; Evans et al., 1998; Ralevic and Burnstock, 1998) . Nevertheless, the cell signaling mechanisms responsible for P2X-and P2Y-mediated increases in renal microvascular smooth muscle cells are not well known.
20-Hydroxyeicosatetraenoic acid (20-HETE), a metabolite of the arachidonic acid cytochrome P450 (P450) pathway, plays an important role in the regulation of renal vascular and tubular function (Ma et al., 1993; Harder et al., 1994; Imig et al., 1996; Hercule and Oyekan, 2000) . 20-HETE in-hibits vascular smooth muscle potassium channels, resulting in membrane depolarization and subsequent activation of L-type Ca 2ϩ channels, leading to vasoconstriction of the afferent arteriole (Lange et al., 1997; Gebremedhin et al., 1998; Imig et al., 1999 Imig et al., , 2000 . Interestingly, P2X receptor inactivation or P450 hydroxylase inhibition significantly attenuates pressure-mediated afferent arteriolar vasoconstrictor responses (Imig et al., 1999; Inscho et al., 2003) . Our previous studies showed that either P450 inhibition or 20-HETE antagonism attenuated the initial vasoconstriction and abolished the sustained vasoconstriction evoked by the P2 receptor agonist ATP (Zhao et al., 2001). In addition, N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS) and 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (20-HEDE) also attenuated the initial vasoconstrictor response and abolished the sustained vasoconstrictor response to the P2X receptor agonist, ␣,␤-methylene-ATP (Zhao et al., 2001) . These data suggest that the P450 metabolite 20-HETE participates in the afferent arteriolar response to activation of P2X receptors. Based on these studies, we hypothesized that endogenous 20-HETE contributes to the increase in [Ca 2ϩ ] i elicited by P2X receptor activation in renal microvascular smooth muscle cells.
Materials and Methods

Tissue Preparation and Renal Microvascular Smooth Muscle Cell Isolation
All studies were performed in compliance with the guidelines and practices dictated by the Medical College of Georgia Advisory Committee for Animal Resources. Suspensions of preglomerular microvascular smooth muscle cells were prepared with a modification of the method previously described (White et al., 2001) . Male SpragueDawley CD-VAF rats (250 -375 g; Charles River Laboratories Inc., Wilmington, MA) were anesthetized with pentobarbital sodium (40 mg/kg i.p.), and the abdominal cavity was exposed to permit cannulation of the abdominal aorta via the superior mesenteric artery. Ligatures were placed around the abdominal aorta at sites proximal and distal to the left and right renal arteries, respectively. The kidneys were cleared of blood by perfusion of the isolated aortic segment with an ice-cold low-calcium physiological salt solution (PSS; pH 7.35) of the following composition: 125 mM NaCl, 5.0 mM KCl, 1.0 mM MgCl 2 , 10.0 mM glucose, 20.0 mM HEPES, 0.1 mM CaCl 2 , and 6% bovine serum albumin. After the kidneys were rinsed of blood, the perfusate was changed to a similar solution containing 1% Evans Blue in low-calcium PSS.
The kidneys were resected from the animal and decapsulated, and the renal medullary tissue was removed. The cortical tissue was pressed through a sieve (180 m), and the sieve retentate was washed several times with ice-cold low-calcium PSS. The vascular tissue remaining on the sieve was transferred to an enzyme solution containing 0.075% collagenase (Roche Diagnostics, Mannheim, Germany), 0.02% dithiothreitol (Sigma-Aldrich, St. Louis, MO), and 0.1% bovine serum albumin dissolved in low-calcium PSS, and this mixture was incubated at 37°C for 30 min. The vascular tissue was removed from the enzyme solution and transferred to a nylon mesh (70 m), where it was vigorously rinsed with ice-cold low-calcium PSS. The mesh containing the retained vascular tissue was transferred to a Petri dish containing ice-cold low-calcium PSS. Segments of interlobular artery with attached afferent arterioles were collected by microdissection using a stereoscope and transferred to a 10-ml dissociation flask. The rinse solution was decanted from the selected vascular segments and replaced with an enzyme solution containing 0.075% papain (Sigma-Aldrich) and 0.02% dithiothreitol (SigmaAldrich) in low-calcium PSS. The tissue was incubated at 37°C for 15 min before being collected by centrifugation (2000g for 50 s). The tissue pellet was transferred to an enzyme solution containing 0.3% collagenase (Roche Diagnostics) and 0.2% soybean trypsin inhibitor (type 1-S; Sigma-Aldrich) in low-calcium PSS at 37°C. After a 15-min incubation period, the mixture was gently triturated and quickly centrifuged (500g for 5 min) to collect the dispersed cells. The supernatant was discarded, and the cells were gently resuspended in 1.0 ml Dulbecco's minimum essential medium (Sigma-Aldrich), supplemented with 20% fetal calf serum (Whittaker Bioproducts, Walkersville, MD), and 100 U/ml penicillin and 200 g/ml streptomycin (Sigma-Aldrich). Cell suspensions were stored on ice until use.
Fluorescence Measurements in Single Microvascular Smooth Muscle Cells
Experiments were performed using a standard microscope-based fluorescence spectrophotometry system (Photon Technology International, Monmouth Junction, NJ) as previously described (White et al., 2001 ). The excitation wavelengths were set at 340 and 380 nm, and the emitted light was collected at 510 Ϯ 20 nm (Photon Technology International). Measurements of fluorescence intensity were collected at 5 data points per second and analyzed with the aid of the Photon Technology International software. Calibration of the fluorescence data were accomplished as previously described (White et al., 2001) .
Measurement of [Ca 2ϩ ] i in single microvascular smooth muscle cells was performed as described previously (White et al., 2001 ). Suspensions of freshly isolated renal microvascular cells were loaded with the calcium-sensitive fluorescent probe, fura-2/acetoxymethyl ester (4.0 M; Molecular Probes, Eugene, OR). An aliquot of cell suspension was transferred to the perfusion chamber (Warner Instruments, Hamden, CT) and mounted to the stage of a Nikon Diaphot inverted microscope. The cells were continuously superfused (1.3 ml/min) with a 1.8 mM calcium PSS solution of the following composition: 125 mM NaCl, 5.0 mM KCl, 1.0 mM MgCl 2 , 10.0 mM glucose, 20.0 mM HEPES, 1.8 mM CaCl 2 , and 0.111 g/l bovine serum albumin. For each experiment, a single microvascular cell was isolated in the optical field by positioning the adjustable sampling window directly over the cell of interest. Neighboring cells and debris are thus excluded from the sampling field, allowing fluorescence emission to be measured only from the background subtracted area, and a new coverslip of cells was used for each experiment.
Experimental Approach
Series 1. Experiments were performed to assess the role of 20-HETE in the microvascular smooth muscle cell response to ATP. For these experiments, cells were challenged with ATP while being bathed in a PSS solution containing the P450 hydroxylase inhibitor DDMS (Wang et al., 1998; Imig et al., 1999) , or the 20-HETE antagonist 20-HEDE (Alonso-Galicia et al., 1999; Zhao et al., 2001 ). Fura-2 fluorescence was monitored in these cells under control conditions (0 -100 s), during exposure to 25 M DDMS in the presence of 1.8 mM Ca 2ϩ (100 -150 s), during subsequent exposure to ATP (10 or 100 M) in combination with DDMS and 1.8 mM Ca 2ϩ (150 -350 s) , and during the recovery period, during which ATP and DDMS were removed from the bathing solution (350 -600 s). Identical studies were performed using 3 M 20-HEDE instead of DDMS. These responses were compared with responses obtained from similar cells challenged in normal calcium PSS without P450 hydroxylase inhibition or 20-HETE antagonism.
Series 2. Studies were performed to further determine the effect of P450 hydroxylase inhibition and 20-HETE antagonism on the increase in [Ca 2ϩ ] i induced by the P2X receptor agonist, ␣,␤-methylene-ATP. Fura-2 fluorescence was monitored in these cells under control conditions (0 -100 s), during exposure to DDMS or 20-HEDE in the presence of 1.8 mM Ca 2ϩ (100 -150 s), during subsequent exposure to ␣,␤-methylene-ATP (10 M) in combination with DDMS or 20-HEDE and 1.8 mM Ca 2ϩ (150 -350 s) , and during the recovery period (350 -600 s). These responses were compared with responses obtained from similar cells challenged with ␣,␤-methylene-ATP alone.
Series 3. Experiments were performed to assess the role of 20-HETE in the renal myocyte response to the P2Y receptor agonist UTP. Fura-2 fluorescence was monitored in these cells under control conditions (0 -100 s), during exposure to DDMS or 20-HEDE in the presence of 1. (Fig. 7) , respectively. 
Results
P450
Discussion
The current studies were performed to determine whether P450 hydroxylase metabolite, 20-HETE, is involved in the [Ca 2ϩ ] i response in the renal microvascular smooth muscle cells to purinoceptor activation. Consistent with our previous studies (Inscho et al., 1999a; White et al., 2001) , ATP and UTP elicited a biphasic response including a peak response followed by a steady-state plateau, whereas ␣,␤-methylene-ATP evoked a transient increase in [Ca 2ϩ ] i that quickly returned to baseline. The P450 hydroxylase inhibitor DDMS and the 20-HETE antagonist 20-HEDE had no effect on baseline renal microvascular smooth muscle cell [Ca 2ϩ Renal hemodynamic control is accomplished by local adjustments in intrarenal vascular resistance. The majority of these resistance adjustments is preglomerular and occurs at the level of the afferent arterioles (Arendshorst and Navar, 1993) . Myogenic and tubuloglomerular feedback-mediated adjustments in preglomerular resistance are the major contributors to renal blood flow autoregulation. Tubuloglomerular feedback is believed to be a major regulatory system, coupling changes in distal tubular flow with preglomerular resistance through the actions of the macula densa. ATP, released from the macula densa, serves as the chemical messenger linking the macula densa with regulation of afferent arteriolar resistance. Regulation of afferent arteriolar resistance involves ATP-dependent activation of P2X receptors that are heavily expressed along the preglomerular but not the postglomerular microvasculature (Mitchell and Navar, 1993; Inscho et al., 1996; Navar et al., 1996; Chan et al., 1998; Inscho, 2001; Bell et al., 2003) . Inactivation of P2 receptors on preglomerular microvessels inhibits autoregulatory behavior Majid et al., 1999) . More recent data suggest a specific role for P2X 1 receptors in the afferent arteriolar autoregulatory response. Pressure-dependent afferent arteriolar diameter responses were abolished by pharmacological blockade of P2X receptors in rats and deletion of P2X 1 receptors in mice (Inscho et al., 2003) . Taken together, these studies strongly support the postulate that P2X 1 receptor activation plays a critical role in mediating afferent arteriolar autoregulatory adjustments.
The cellular signaling mechanisms responsible for P2 receptor vasoconstriction are not well defined. ATP-mediated afferent arteriolar vasoconstriction is largely dependent on the influx of extracellular Ca 2ϩ and the sustained vasoconstriction is maintained by Ca 2ϩ influx through voltage-dependent L-type Ca 2ϩ channels (Inscho et al., 1995 (Inscho et al., , 1999a Navar et al., 1996; Inscho and Cook, 2002) . P2 receptor activation results in the release of arachidonic acid from membrane phospholipids in glomerular mesangial cells and rat astrocytes (Pfeilschifter, 1990 ; Schulze-Lohoff et al., Bolego et al., 1997) . Our previous studies showed that P450 inhibition or 20-HETE antagonism significantly attenuated both the initial and sustained afferent arteriolar constrictor responsiveness to ATP (Zhao et al., 2001 ). These data demonstrate that the P450 metabolite 20-HETE participates in the afferent arteriolar response to P2 receptor activation. To determine whether 20-HETE contributes to the afferent arteriolar response to P2 receptor activation by influencing the microvascular smooth muscle cell calcium signaling, we further investigated the effect of DDMS or 20-HEDE on the renal myocyte [Ca 2ϩ ] i response to ATP. Our studies showed that both DDMS and 20-HEDE significantly attenuated the initial [Ca 2ϩ ] i responses to ATP. These data suggest that 20-HETE is involved in the renal microvascular smooth muscle cell [Ca 2ϩ ] i response to P2 receptor activation. P2 receptors were first defined by Burnstock in 1978 (Burnstock, 1978 . Since then, P2 receptors have grown into a large family of receptors divided into two major categories classified as P2X and P2Y Fredholm et al., 1994 Fredholm et al., , 1997 Ralevic and Burnstock, 1998 ). P2X receptors are described as having two membrane-spanning domains and function as ligand-gated channels Ralevic and Burnstock, 1998) . P2Y receptors have seven membrane-spanning domains and function as G protein-coupled receptors Ralevic and Burnstock, 1998) . Previous studies have shown that renal microvascular smooth muscle cell [Ca 2ϩ ] i responses to P2 receptor stimulation with ATP involve the activation of both P2X and P2Y receptor subtypes (Inscho et al., 1999a; White et al., 2001 ). Each receptor type activates different calcium signaling pathways. Exposure of renal myocytes to the P2X-selective agonist ␣,␤-methylene-ATP results in an elevation of [Ca 2ϩ ] i through activation of calcium influx pathways (White et al., 2001) . The magnitude and time course of the response to ␣,␤-methylene-ATP are markedly different from those evoked by an equimolar concentration of ATP (White et al., 2001) . The average peak response elicited by 10 M ␣,␤-methylene-ATP was ϳ34% of the response obtained with 10 M ATP. The response to ␣,␤-methylene-ATP was transient whereas the response to ATP exhibited a sustained elevation of [Ca 2ϩ ] i . In the current study, DDMS markedly reduced the [Ca 2ϩ ] i response to the P2X receptor agonist ␣,␤-methylene-ATP. The inability of 20-HEDE to significantly decrease the renal microvascular smooth muscle cell Ca 2ϩ response to ␣,␤-methylene-ATP is perplexing. These data are not consistent with the afferent arteriolar diameter responses to ATP and ␣,␤-methylene-ATP or the renal myocyte Ca 2ϩ response to ATP in the presence of 20-HEDE. Even though there was a slight trend for a decreased ␣,␤-methylene-ATP response in cells treated with 20-HEDE, we have no real compelling explanation for the lack of a 20-HEDE effect in this experimental setting. Overall, the majority of afferent arteriolar and renal myocyte experiments would suggest that endogenous 20-HETE may contribute to the P2X receptor-mediated afferent arteriolar vasoconstriction by influencing calcium influx in preglomerular microvascular smooth muscle cells.
P2Y receptor activation stimulates vascular smooth muscle cell [Ca 2ϩ ] i in a strikingly different way. The P2Y receptor agonist UTP is purported to interact primarily with G protein-regulated P2Y receptors and is reported to activate phospholipase C (Dubyak and el-Moatassim, 1993; Abbracchio and Conigrave and Jiang, 1995) . Previous studies showed that the mechanisms by which UTP and ATP elevate [Ca 2ϩ ] i seem to be substantially different although they stimulate similar increases in [Ca 2ϩ ] i overall (Inscho et al., 1999a; Inscho and Cook, 2002) . ATP used both calcium influx and calcium mobilization, whereas the response to UTP seems to arise almost exclusively from the release of calcium from intracellular stores. Removal of calcium from the extracellular medium or blockade of calcium influx through L-type calcium channels had no perceptible effect on the magnitude or time course of UTP-mediated increases in [Ca 2ϩ ] i . This suggests that binding of UTP to its receptor stimulates a signal transduction cascade designed to access stored calcium. On the basis of findings generated by other investigators, UTP-mediated activation of the phospholipase C/inositol trisphosphate/diacylglycerol pathway represents the most likely signal transduction mechanism. In our current study, stimulation of the cells with UTP induced a rapid increase in intracellular Ca 2ϩ levels, followed by a slow decrease to basal levels or cytoplasmic Ca 2ϩ oscillation. P450 hydroxylase inhibition and 20-HETE antagonism did not alter the initial microvascular smooth muscle cell [Ca 2ϩ ] i response to UTP. Whether P450 hydroxylase inhibition or 20-HETE antagonism affects the oscillatory response is still not clear. Taken together, these data suggest that 20-HETE is not involved in the P2Y receptor-activated calcium signaling pathway, which is consistent with our previous finding that 20-HETE is not involved in the P2Y receptor-mediated preglomerular vasoconstriction.
Previous studies have implicated the arachidonic acid metabolite 20-HETE as one paracrine factor mediating tubuloglomerular feedback and autoregulatory related signals to the afferent arterioles. 20-HETE is produced by renal vascular smooth muscle cells and is a potent constrictor that depolarizes vascular smooth muscle cells by blocking calciumactivated potassium channels Maier and Roman, 2001 ). Inhibition of 20-HETE formation blocks the myogenic response of isolated renal arterioles in vitro (Maier and Roman, 2001) . In our experiments, we observed the influence of DDMS and 20-HEDE on the renal microvascular smooth muscle cell Ca 2ϩ response to ATP and found that DDMS or 20-HEDE significantly decreased the peak [Ca 2ϩ ] i response. Interestingly, P2 receptor activation liberates arachidonic acid from membrane phospholipids (Pfeilschifter, 1990) , which would provide the substrate for P450 hydroxylase enzymes and 20-HETE production. Additional experiments demonstrated that renal microvascular smooth muscle cell Ca 2ϩ levels increased in response to 20-HETE. The Ca 2ϩ response to 20-HETE was rapid in onset and had a time course and magnitude similar to that of P2X receptor activation. 20-HETE has been previously shown to increase intracellular Ca 2ϩ levels in smooth muscle cells from canine renal arteries (Ma et al., 1993) . Our laboratory has also demonstrated that the afferent arteriolar constrictor response to 20-HETE involves inactivation of potassium channels that results in smooth muscle cell depolarization and Ca 2ϩ channel activation . Taken together, these results suggest that P450 hydroxylase metabolite 20-HETE is produced by renal microvascular smooth muscle cells and contributes to the renal preglomerular microvascular response to ATP.
In summary, both DDMS and 20-HEDE attenuated the initial [Ca 2ϩ ] i response evoked by the P2 receptor agonist ATP. In addition, DDMS also attenuated the renal myocyte [Ca 2ϩ ] i response to the P2X receptor agonist, ␣,␤-methylene-ATP. In contrast, DDMS and 20-HEDE had no effect on [Ca 2ϩ ] i to the P2Y receptor agonist UTP. These data demonstrate that the P450 metabolite 20-HETE is involved in the renal microvascular smooth muscle cell calcium response to P2X receptor activation.
